Thus far, approximately 40 companies worldwide, including Codiak Biosciences, Evox Therapeutics, Tavec Pharmaceuticals, Carmine Therapeutics, Anjarium, and Micromedmark Biotech, have developed exosome-based therapies, which are expected to provide cost-effective and more accurate targeted therapies in the clinic ( However, challenges, such as large-scale production, purity, and batch homogeneity of exosomes, still limit their clinical application
ACS Pharm
Helicobacter Pylori Vacuolating Cytotoxin, VacA, is Responsible for Gastric Ulceration
Evidence can be limited, mixed, preclinical, observational, old, formulation-specific, or otherwise insufficient to support an FDA-approved indication